Entera Bio (ENTX) Share-based Compensation (2021 - 2026)
Entera Bio (ENTX) recorded quarterly Share-based Compensation of $672000.0 in Q1 2026, down 5.35% on a QoQ basis from $710000.0 in Q4 2025, and up 11.26% year-over-year from $604000.0 in Q1 2025.
Entera Bio (ENTX) Share-based Compensation (2021 - 2026) Analysis & Trends
Entera Bio has disclosed Share-based Compensation across 6 years of filings, most recently posting $672000.0 for Q1 2026.
- Quarterly Share-based Compensation rose 11.26% year-over-year to $672000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.8 million (up 4.53% YoY) and the FY2025 annual result came in at $2.8 million, up 7.59% from the prior year.
- Share-based Compensation eased to $672000.0 in Q1 2026, from $710000.0 in the prior quarter.
- Over five years, Share-based Compensation peaked at $964000.0 in Q1 2022 and troughed at $110000.0 in Q3 2022.
- A 5-year average of $583176.5 and a median of $566000.0 in 2024 frame the typical range for Share-based Compensation.
- Annual changes were most pronounced in 2022 — Share-based Compensation sank 82.48% — and 2023, when it surged 248.18%.
- Tracing ENTX's Share-based Compensation over 5 years: stood at $477000.0 in 2022, then slumped by 33.33% to $318000.0 in 2023, then surged by 77.99% to $566000.0 in 2024, then grew by 25.44% to $710000.0 in 2025, then retreated by 5.35% to $672000.0 in 2026.
- Business Quant data shows ENTX's Share-based Compensation at $672000.0 in Q1 2026, $710000.0 in Q4 2025, and $927000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | 305,000.00 |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 166.40 Mn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | 26.47 Mn |
| 10 | Entera Bio | 56.59 Mn | 52.45 Mn | - | 672,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 672,000.00 |
| Mar 31, 2026 | 672,000.00 |
| Dec 31, 2025 | 710,000.00 |
| Dec 31, 2025 | 710,000.00 |
| Sep 30, 2025 | 927,000.00 |
| Sep 30, 2025 | 927,000.00 |
| Jun 30, 2025 | 509,000.00 |
| Jun 30, 2025 | 509,000.00 |
| Mar 31, 2025 | 604,000.00 |
| Mar 31, 2025 | 604,000.00 |
| Dec 31, 2024 | 566,000.00 |
| Dec 31, 2024 | 566,000.00 |
| Sep 30, 2024 | 928,000.00 |
| Sep 30, 2024 | 928,000.00 |
| Jun 30, 2024 | 598,000.00 |
| Jun 30, 2024 | 598,000.00 |
| Mar 31, 2024 | 464,000.00 |
| Mar 31, 2024 | 464,000.00 |
| Dec 31, 2023 | 318,000.00 |
| Dec 31, 2023 | 318,000.00 |